MWNA
BNR

Marshall Wace North America’s Burning Rock Biotech BNR Stock Holding History

Marshall Wace North America’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,313
Closed -$1.17M – 1219
2020
Q2 		$1.17M Buy
+4,313
New +$1.18M 0.01% 722

Other funds holding BNR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Marshall Wace North America's BNR Position: Q3 2020 in Review

Marshall Wace North America sold out of Burning Rock Biotech (BNR) in Q3 2020, closing a stake of 4,313 shares — an estimated $1.17M sold.

Marshall Wace North America first reported a position in BNR in Q2 2020 and held it in 1 quarter. The position peaked at $1.17M in Q2 2020. 38 funds tracked by Wall St. Rank hold BNR as of Q3 2020.

  • Marshall Wace North America reported no remaining Burning Rock Biotech position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 4,313 Burning Rock Biotech shares in Q3 2020, an estimated $1.17M.
  • Marshall Wace North America first reported a position in Burning Rock Biotech in Q2 2020 and held it in 1 quarter.
  • Marshall Wace North America's Burning Rock Biotech position peaked at $1.17M in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.